Home
Subscribe (free)
About NaturalNews
Contact Us
Write for NaturalNews
Media Info
Advertising Info
Vytorin

Vytorin Drug Shows No Benefit Over Older, Cheaper Cholesterol Drugs

Saturday, June 14, 2008 by: David Gutierrez, staff writer
Tags: Vytorin, health news, Natural News


Most Viewed Articles
https://www.naturalnews.com/023433_drug_Vytorin_cholesterol.html
Delicious
diaspora
Print
Email
Share

(NaturalNews) After a long and controversial delay, drug-makers Merck and Schering-Plough have released the results of a study showing that cholesterol drug Vytorin provides no benefit over older drugs in preventing the buildup of artery plaque.

Vytorin is a combination of Merck and Schering's drug ezetimibe - marketed as Zetia, Ezetrol and Ezemibe - and the statin Zocor. Because ezetimibe lowers cholesterol by a different mechanism than the older statin drugs, doctors often prescribe the two types of drugs in combination.

According to the results recently released after a controversial 18-month delay, patients taking Vytorin had a 40 percent larger reduction in cholesterol than patients taking Zocor alone, but there was no significance in the rates of plaque buildup, heart attacks or death between the two groups.

Study participants taking Vytorin actually suffered slightly more arterial plaque buildup, heart attacks, heart procedures and cardiovascular death than those taking only Zocor, but the small study size made it impossible to determine if those results were significant or due only to a statistical fluke.

To date, no studies have demonstrated a health benefit to ezetimibe or Vytorin, in spite of the well-documented cholesterol-lowering effect. Critics charge that the drug exposes patients to the risk of potentially dangerous side effects for no substantial benefit.

A scandal recently emerged when it was revealed that Merck and Schering had failed to publish the results of studies linking ezetimibe to liver damage.

"Physicians should only use ezetimibe or Vytorin as a last resort," said prominent cardiologist Steven Nissen. "It should not be used as a routine therapy for high cholesterol unless we see some additional evidence of benefit."

According to some researchers, the results of the recent study might have been skewed by the prevalence among the participants of a genetic disease that predisposes people to high cholesterol. This meant that many of the participants had already been taking statins for many years. But according to Nissen, the benefits of Vytorin should have been even more pronounced in such a group than in the general population.

Join the Health Ranger's FREE email newsletter
Get breaking news alerts on GMOs, fluoride, superfoods, natural cures and more...
Your privacy is protected. Unsubscribe at any time. | Learn more...

comments powered by Disqus

Get alerted on heavy metals and pesticide test results for foods and supplements

Natural News is about to begin releasing lab test results for off-the-shelf food, supplement and pet food products, covering heavy metals, nutritive minerals, pesticides and herbicides. These details will be released exclusively to Natural News email newsletter subscribers (FREE) and will NOT be publicly posted on the website. To be alerted, join our free email newsletter now, and watch for lab test results in the weeks ahead.

Enter your email address below to subscribe to our email announcement list (but don't use gmail). Your privacy is protected and you can unsubscribe at any time. If you don't join our email list, you may never see our valuable content again via Facebook, Google or YouTube. CENSORSHIP has now reached EXTREME levels across the 'net. The truth is being suffocated. Subscribe now if you want to escape the delusional bubble of false reality being pushed by Google and Facebook.

Once you click subscribe, we will send you an email asking you to confirm your free subscription.